Sarepta Therapeutics Inc (SRPT): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Sarepta Therapeutics ( SRPT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.5%. By the end of trading, Sarepta Therapeutics rose 78 cents (2.4%) to $33.03 on average volume. Throughout the day, 1.7 million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1.3 million shares. The stock ranged in a price between $31.90-$33.60 after having opened the day at $32 as compared to the previous trading day's close of $32.25. Other companies within the Health Care sector that increased today were: Nymox Pharmaceutical Corporation ( NYMX), up 25.6%, Atossa Genetics ( ATOS), up 24.5%, IGI ( IG), up 16.8%, and China Biologic Products ( CBPO), up 13.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of serious and life-threatening rare and infectious diseases. Sarepta Therapeutics has a market cap of $851.1 million and is part of the drugs industry. Shares are up 25% year to date as of the close of trading on Friday. Currently there are six analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share.

On the negative front, Pernix Therapeutics Holdings ( PTX), down 12%, Idera Pharmaceuticals ( IDRA), down 10.8%, iBio ( IBIO), down 10%, and Supernus Pharmaceuticals ( SUPN), down 9.8%, were all laggards within the health care sector with Amgen ( AMGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.